Day One Biopharmaceuticals, Inc.DAWNEarnings & Financial Report
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
Revenue
$93.8M
Gross Profit
N/A
Operating Profit
$29.6M
Net Profit
$37.0M
Gross Margin
N/A
Operating Margin
31.6%
Net Margin
39.5%
YoY Growth
N/A
EPS
$0.38
Day One Biopharmaceuticals, Inc. Q3 FY2024 Financial Summary
Day One Biopharmaceuticals, Inc. reported revenue of $93.8M for Q3 FY2024, with a net profit of $37.0M (up 180.3% YoY) (39.5% margin).
Key Financial Metrics
| Total Revenue | $93.8M |
|---|---|
| Net Profit | $37.0M |
| Gross Margin | N/A |
| Operating Margin | 31.6% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Day One Biopharmaceuticals, Inc. Q3 FY2024 revenue of $93.8M breaks down across 2 segments, led by License at $73.7M (78.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| License | $73.7M | 78.6% |
| Products | $20.1M | 21.4% |
Day One Biopharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Day One Biopharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as License and Products) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 |
|---|---|---|---|---|
| License | — | — | — | $73.7M |
| Products | $38.5M | $33.6M | $30.5M | $20.1M |
Day One Biopharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Day One Biopharmaceuticals, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $39.8M | -57.6% | $-19.7M | -49.6% |
| Q2 FY2025 | $33.9M | +313.9% | $-30.3M | -89.4% |
| Q1 FY2025 | $30.8M | — | $-36.0M | -117.0% |
| Q3 FY2024 | $93.8M | — | $37.0M | 39.5% |
| Q1 FY2024 | $0 | — | $-62.4M | N/A |
| Q3 FY2023 | $0 | — | $-46.1M | N/A |
Income Statement
| Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $93.8M | $30.8M | $33.9M | $39.8M |
| YoY Growth | N/A | N/A | N/A | N/A | 313.9% | -57.6% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $414.2M | $326.6M | $600.8M | $534.4M | $519.0M | $513.8M |
| Liabilities | $24.6M | $29.8M | $45.3M | $54.8M | $58.2M | $62.9M |
| Equity | $389.6M | $296.8M | $555.5M | $479.5M | $460.8M | $450.9M |
Cash Flow
| Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-37.1M | $-49.7M | $50.8M | $-59.0M | $-24.8M | $-5.8M |